Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Newly diagnosed multiple myeloma.

Donna M Weber1

  • 1University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Box #429, Houston, TX 77030, USA. dmweber@mdanderson.org

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Blood cancer journal·2026
Same author

Analysis of Social Drivers of Health, Race, and Ethnicity With Survival in Myeloma Patients.

Clinical lymphoma, myeloma & leukemia·2026
Same author

A Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis.

American journal of hematology·2026
Same author

Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy.

Blood cancer journal·2025
Same author

Phase I study of pomalidomide in relapsed or refractory Waldenström macroglobulinaemia.

British journal of haematology·2025
Same author

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel.

Blood advances·2025
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Melphalan and prednisone (MP) is standard for multiple myeloma (MM), but new agents like thalidomide show promise. Clinical trials are recommended for newly diagnosed MM patients to explore novel therapies and improve outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Pharmacology

Background:

  • Melphalan combined with prednisone (MP) is the standard initial therapy for multiple myeloma (MM).
  • Current combination chemotherapy regimens offer only modest survival benefits over MP.
  • Intensive myeloablative regimens with stem cell support show gains, particularly for refractory or relapsed MM.

Purpose of the Study:

  • To evaluate the efficacy of novel therapeutic agents and regimens for previously untreated multiple myeloma.
  • To identify optimal treatment strategies that preserve stem cell collection capabilities.
  • To guide the selection of first-line therapies for newly diagnosed multiple myeloma patients.

Main Methods:

  • Review of existing studies on melphalan/prednisone (MP), myeloablative regimens, and VAD (vincristine/doxorubicin/dexamethasone).

Related Experiment Videos

  • Analysis of emerging data on novel agents including thalidomide, immunomodulatory drugs, and proteasome inhibitors.
  • Consideration of clinical trial participation for patients with newly diagnosed or previously untreated MM.

    • Main Results:

    • Thalidomide/dexamethasone demonstrates high response rates (65-75%) in previously untreated MM.
    • VAD regimens show high response rates (50-70%) but have not improved survival when used early.
    • Novel agents show activity in resistant myeloma and are candidates for combination therapies.

    Conclusions:

    • Novel agents like thalidomide offer promising alternatives for previously untreated multiple myeloma.
    • Thalidomide/dexamethasone, followed by myeloablative therapy with stem cell support, may become the preferred treatment.
    • Clinical trials are crucial for evaluating new agents and optimizing treatment for newly diagnosed MM.